Hims & Hers Health (HIMS) is presented as a compelling investment opportunity following outstanding Q3 results that saw revenue growth rebound to 49% year-over-year. The company's profits are growing even faster than its revenue, demonstrating strong operational efficiency and a successful shift to high-value personalized subscriptions. The core thesis is that HIMS is significantly undervalued by the market and should be valued more like a high-growth software company. With its strong performance, the stock price could potentially grow in line with its revenue, suggesting a potential upside of nearly 50% per year. Future growth catalysts to watch include the launch of new treatments for menopause and testosterone.

Hims & Hers Health, Inc. (HIMS)

• The podcast host is extremely positive about HIMS following its Q3 earnings report, calling the results "outstanding."
• Revenue Growth Rebounded: The host's primary focus was on revenue growth, which had slowed in Q2 after the company ended a partnership with Novo Nordisk. Q3 growth not only stopped the decline but exceeded the growth rates of both Q1 and Q2, alleviating major market fears.
  • Year-over-year revenue growth was 49%.
  • Q3 revenue was $599 million, significantly beating the estimated $479 million.
• Strong Profitability and Operating Leverage: The company's profits are growing even faster than its revenue, a key sign of a healthy, scaling business.
  • Adjusted EBITDA (a proxy for cash flow) grew 53% year-over-year.
  • The company is achieving this by bringing more operations in-house, such as manufacturing its own pills and peptides, which lowers costs.
• Impressive Customer Metrics:
  • The number of subscribers grew by 21%.
  • Monthly Average Revenue Per User (ARPU) increased to $80, up from $67 a year ago. The host notes this was in the mid-$50s previously.
  • The host speculates that ARPU could potentially reach $200 per month within 5 to 10 years.
  • A majority of customers (1.6 million out of 2.3 million) are now on personalized subscription plans, which the host sees as the "future of medicine."
• Valuation and Future Outlook:
  • The host believes the stock is "very, very cheap" and is being "dismissed by the market."
  • He argues it should be valued more like a high-growth SaaS (Software-as-a-Service) company due to its strong recurring subscription revenue.
  • The company's "Rule of 40" score is 60, which is excellent (a score above 40 is considered very good for a healthy growth company).
  • The host believes analyst predictions for 2026 revenue growth (47%) are too pessimistic, especially with the launch of new treatments for menopause and testosterone.

Takeaways

• Bullish Sentiment: The analysis is overwhelmingly bullish. The Q3 report is seen as proof that the company's growth engine is strong and not dependent on a single partnership.
• Growth Story is Intact: For investors concerned about the post-Novo slowdown, this quarter suggests the core business is resilient and accelerating once again. The company is successfully growing its subscriber base while also increasing the amount each customer spends.
• Potential for Undervaluation: The core investment thesis presented is that HIMS is a high-growth, increasingly profitable company whose stock price has not yet caught up to its fundamental performance. The host suggests that if the stock's price-to-sales ratio simply remains constant, the stock price could grow in line with its impressive revenue growth (e.g., ~50% per year).
• Future Growth Catalysts: Keep an eye on the adoption of the new menopause and testosterone product lines, as these could provide upside to current growth expectations. The continued shift of customers to higher-value personalized plans is another key trend to watch.
• Key Metric to Watch: The podcast highlights revenue growth as the most important metric. As long as the company continues to post strong top-line growth and improve profitability, the bullish case remains strong.